Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Syndax (SNDX) Q4 2025 Earnings Call Transcript

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration.

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Syndax Pharmaceuticals reported mixed Q2 2025 results, beating revenue estimates with $37.96M but posting an EPS loss of ($0.83). Revuforj sales surged 43%, while shares dipped 3.66% post-earnings.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.